Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Gadopentetate dimeglumine
Overview
What is Magnevist?
Magnevist (brand of gadopentetate dimeglumine) injection is the N-methylglucamine salt of the gadolinium complex of diethylenetriamine pentaacetic acid, and is an injectable contrast medium for magnetic resonance imaging (MRI). Magnevist Injection is provided as a sterile, clear, colorless to slightly yellow aqueous solution for intravenous injection.
Magnevist Injection is a 0.5-mol/L solution of 1-deoxy-1-(methylamino)-D-glucitol dihydrogen [N,N-bis[2-[bis(carboxymethyl)amino]ethyl] glycinato (5-) ]gadolinate(2-)(2:1) with a molecular weight of 938, an empirical formula of CHGdNO, and has the following structural formula:
Each mL of Magnevist injection contains 469.01 mg gadopentetate dimeglumine, 0.99 mg meglumine, 0.40 mg diethylenetriamine pentaacetic acid, and water for injection. Magnevist injection contains no antimicrobial preservative.
Magnevist Injection has a pH of 6.5 to 8.0. Pertinent physicochemical data are noted below:
Magnevist injection has an osmolality 6.9 times that of plasma, which has an osmolality of 285 mOsmol/kg water. Magnevist injection is hypertonic under conditions of use.
What does Magnevist look like?
What are the available doses of Magnevist?
Magnevist contains 0.5 mmol gadopentetate dimeglumine/mL (equivalent to 469.01 mg gadopentetate dimeglumine/mL) and is available in vials and prefilled syringes. ()
What should I talk to my health care provider before I take Magnevist?
How should I use Magnevist?
Magnevist injection is indicated for use with magnetic resonance imaging (MRI) in adults, and pediatric patients (2 years of age and older) to visualize lesions with abnormal vascularity in the brain (intracranial lesions), spine and associated tissues. Magnevist injection has been shown to facilitate visualization of intracranial lesions including but not limited to tumors.
The recommended dosage of Magnevist injection is 0.2 mL/kg (0.1 mmol/kg) administered intravenously, at a rate not to exceed 10 mL per 15 seconds. Dosing for patients in excess of 286 lbs has not been studied systematically.
To ensure complete injection of Gadopentetate dimeglumine, administer 5-mL normal saline flush after the injection. The imaging procedure should be completed within 1 hour of injection of Magnevist injection.
Visually inspect for particulate matter and discoloration prior to administration. Do not use the solution if it is discolored, if particulate matter is present or if the container appears damaged.
Discard any unused portion in accordance with regulations dealing with the disposal of such materials.
What interacts with Magnevist?
Sorry No Records found
What are the warnings of Magnevist?
Sorry No Records found
What are the precautions of Magnevist?
Sorry No Records found
What are the side effects of Magnevist?
Sorry No records found
What should I look out for while using Magnevist?
Magnevist is contraindicated in patients with:
What might happen if I take too much Magnevist?
Systemic consequences associated with overdosage of Magnevist injection have not been reported.
How should I store and handle Magnevist?
Store olanzapine tablets at 20°C to 25°C (68°F to 77°F); excursions permitted from 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].Protect olanzapine tablets from light and moisture. Store olanzapine tablets at 20°C to 25°C (68°F to 77°F); excursions permitted from 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].Protect olanzapine tablets from light and moisture. Nabumetone Tablets, USP, for oral administration, are available as 500 mgOval-shaped, white film coated tablets, debossed “ 145" on one side, plain on the other side and supplied as: bottles of 20, 30, 60 and 120Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].Dispense contents in a tight, light-resistant container as defined in the USP with a child-resistant closure, as required.KEEP TIGHTLY CLOSED.Nabumetone Tablets, USP, for oral administration, are available as 500 mgOval-shaped, white film coated tablets, debossed “ 145" on one side, plain on the other side and supplied as: bottles of 20, 30, 60 and 120Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].Dispense contents in a tight, light-resistant container as defined in the USP with a child-resistant closure, as required.KEEP TIGHTLY CLOSED.Nabumetone Tablets, USP, for oral administration, are available as 500 mgOval-shaped, white film coated tablets, debossed “ 145" on one side, plain on the other side and supplied as: bottles of 20, 30, 60 and 120Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].Dispense contents in a tight, light-resistant container as defined in the USP with a child-resistant closure, as required.KEEP TIGHTLY CLOSED.Nabumetone Tablets, USP, for oral administration, are available as 500 mgOval-shaped, white film coated tablets, debossed “ 145" on one side, plain on the other side and supplied as: bottles of 20, 30, 60 and 120Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].Dispense contents in a tight, light-resistant container as defined in the USP with a child-resistant closure, as required.KEEP TIGHTLY CLOSED.Nabumetone Tablets, USP, for oral administration, are available as 500 mgOval-shaped, white film coated tablets, debossed “ 145" on one side, plain on the other side and supplied as: bottles of 20, 30, 60 and 120Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].Dispense contents in a tight, light-resistant container as defined in the USP with a child-resistant closure, as required.KEEP TIGHTLY CLOSED.Nabumetone Tablets, USP, for oral administration, are available as 500 mgOval-shaped, white film coated tablets, debossed “ 145" on one side, plain on the other side and supplied as: bottles of 20, 30, 60 and 120Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].Dispense contents in a tight, light-resistant container as defined in the USP with a child-resistant closure, as required.KEEP TIGHTLY CLOSED.Nabumetone Tablets, USP, for oral administration, are available as 500 mgOval-shaped, white film coated tablets, debossed “ 145" on one side, plain on the other side and supplied as: bottles of 20, 30, 60 and 120Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].Dispense contents in a tight, light-resistant container as defined in the USP with a child-resistant closure, as required.KEEP TIGHTLY CLOSED.
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Magnevist is a paramagnetic agent and, as such, it develops a magnetic moment when placed in a magnetic field. The relatively large magnetic moment produced by the paramagnetic agent results in a relatively large local magnetic field, which can enhance the relaxation rates of water protons in the vicinity of the paramagnetic agent.
Non-Clinical Toxicology
Magnevist is contraindicated in patients with:Gadolinium-based contrast agents (GBCAs) increase the risk for nephrogenic systemic fibrosis (NSF) among patients with impaired elimination of the drugs. Avoid use of GBCAs among these patients unless the diagnostic information is essential and not available with non-contrast enhanced MRI or other modalities. The GBCA-associated NSF risk appears highest for patients with chronic, severe kidney disease (GFR < 30 mL/min/1.73m) as well as patients with acute kidney injury. Do not administer Magnevist to these patients. The risk appears lower for patients with chronic, moderate kidney disease (GFR 30- 59 mL/min/1.73m) and little, if any, for patients with chronic, mild kidney disease (GFR 60- 89 mL/min/1.73m). NSF may result in fatal or debilitating fibrosis affecting the skin, muscle, and internal organs. Report any diagnosis of NSF following Magnevist administration to Bayer HealthCare (1-888-842-2937) or FDA (1-800-FDA-1088 or www.fda.gov/medwatch).
Screen patients for acute kidney injury and other conditions that may reduce renal function. Features of acute kidney injury consist of rapid (over hours to days) and usually reversible decrease in kidney function, commonly in the setting of surgery, severe infection, injury, or drug-induced kidney toxicity. Serum creatinine levels and estimated GFR may not reliably assess renal function in the setting of acute kidney injury. For patients at risk for chronically reduced renal function (for example, age > 60 years, diabetes mellitus or chronic hypertension), estimate the GFR through laboratory testing.
Among the factors that may increase the risk for NSF are repeated or higher than recommended doses of a GBCA and degree of renal impairment at the time of exposure. Record the specific GBCA and the dose administered to a patient. When administering Gadopentetate dimeglumine, do not exceed the recommended dose and allow a sufficient period of time for elimination of the drug prior to re-administration and.
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).